Oncology Meta-model/MBMAPopPKADC

HER2 ADC population PK

Reference paper ↗

A two-compartment population PK model for HER2-directed antibody–drug conjugates, representing central and peripheral disposition, concentration, and cumulative exposure across dose levels.

Therapeutic
Trastuzumab emtansine or trastuzumab deruxtecan, trastuzumab emtansine, T-DM1, trastuzumab deruxtecan, T-DXd, trastuzumab
Modality
Antibody–drug conjugate (ADC)
Target
HER2 / ERBB2
Disease
HER2-positive cancers
Model type
Meta-model/MBMA, PopPK, ADC

Complete model workspace

Checking workspace access…

Parameters
4
States
4
Equations
4
Derived outputs
7

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

T-DM1 0.3 mg/kg cycle-1 fixed-effect

How does dose change HER2 ADC concentration and cumulative exposure? Explore this intervention regimen through Central HER2 ADC concentration, Peripheral HER2 ADC concentration, Cumulative ADC exposure.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–21 day; step 0.025

InputDefaultAvailable range
Systemic clearance0.809 L/day0.4045–1.214 L/day
Central distribution volume3.283 L1.642–4.925 L
Intercompartmental clearance1.12 L/day0.56–1.68 L/day
Peripheral distribution volume0.748 L0.374–1.122 L

Expected readouts

Central HER2 ADC concentration · Peripheral HER2 ADC concentration · Exposure (AUC) (ng*day/mL)

Adjustable model parameters

This public explorer exposes 4 curated parameters. Sign in to edit all 4 declared model parameters.

How the model represents the biology

A two-compartment population PK model for HER2-directed antibody–drug conjugates, representing central and peripheral disposition, concentration, and cumulative exposure across dose levels.

How does an intravenous HER2-directed ADC distribute and accumulate exposure?An intravenous ADC enters the central pool, exchanges reversibly with a peripheral pool, undergoes systemic clearance, and contributes central concentration to cumulative exposure.BIOLOGY OVERVIEWHow does an intravenous HER2-directed ADC distribute and accumulate exposure?IV ADC inputT-DM1 or T-DXd regimenCentral ADC poolPlasma amount andconcentrationPeripheral ADC poolReversible distribution spaceSystemic clearanceLinear loss from central ADCCumulative exposureIntegral of centralconcentrationPRIMARY READOUTSCentral ADC concentrationCentral ADC concentrationPeripheral ADC concentrationPeripheral ADC concentrati…Cumulative ADC exposureCumulative ADC exposure

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: This is two-compartment PK only; HER2 binding, tumor uptake, linker cleavage, payload release, and tumor killing are not represented.

Modeled relationships (4)
  • IV ADC input → Central ADC pool: IV input (flow)
  • Central ADC pool ↔ Peripheral ADC pool: distribution (reversible exchange)
  • Central ADC pool → Systemic clearance: linear CL (loss)
  • Central ADC pool → Cumulative exposure: integrates C (production)

Modeled relationships: IV ADC input to Central ADC pool: IV input (flow); Central ADC pool reversibly exchanges with Peripheral ADC pool: distribution (reversible exchange); Central ADC pool to Systemic clearance: linear CL (loss); Central ADC pool to Cumulative exposure: integrates C (production).

Primary readouts: Central ADC concentration; Peripheral ADC concentration; Cumulative ADC exposure.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID asiimwe_2025_adc_mbma_cui_poppk.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics